ImmuneBridge website screenshot

ImmuneBridge

ImmuneBridge is a San Francisco biotech company building a first-in-class integrated screening and manufacturing platform for allogeneic cell therapies. The company screens and expands stem cells from multiple sources (umbilical cord blood, mobilized blood, bone marrow), uses high-throughput automated assays with machine-learning models to predict donor and process performance early, and scales production with IBR403, a small molecule enabling up to 100,000-fold expansion of hematopoietic stem cells. The stated goal is to manufacture tens of thousands of affordable, high-quality immune cell doses (HSCs, NK cells, T cells, and more) from a single cord blood unit. ImmuneBridge is backed by Insight Partners, NFX Bio, M Ventures, and other institutional investors. This profile was enriched by the API Evangelist pipeline; the company publishes no public API or developer surface.

ImmuneBridge is profiled on the APIs.io network. Tagged areas include Company, Biotech, Cell Therapy, Therapeutics, and Immunology.

ImmuneBridge’s developer surface includes engineering blog and 3 more developer resources.

🌐 Visit website 📡 Source on GitHub
11.2/100 minimal ▬ flat Agent 0/100 human only Full breakdown ↓
scored 2026-07-27 · rubric v0.5
0 APIs
CompanyBiotechCell TherapyTherapeuticsImmunologyBioprocessingLife Sciences

Kin Score

Kin Score Kin Score How this is scored →
scored 2026-07-27 · rubric v0.5
Composite quality — 11.2/100 · minimal
Contract Quality 0.0 / 25
Developer Ergonomics 0.4 / 20
Commercial Clarity 2.1 / 20
Operational Transparency 0.0 / 13
Governance 0.0 / 12
Discoverability 6.8 / 10
Agent readiness — 0/100 · human only
Machine-Readable Contract 0 / 18
Agentic Access Contract 0 / 15
MCP Server 0 / 12
Machine-Readable Auth 0 / 10
Idempotency 0 / 9
Stable Error Semantics 0 / 8
Request/Response Examples 0 / 7
Rate-Limit Signaling 0 / 7
Typed Event Surface 0 / 6
Agent Skills 0 / 5
Well-Known Catalog 0 / 4
Consent & Bot Identity 0 / 3
Improve this rating by publishing the missing artifacts — every area above can be raised, and the full rubric is at apis.io/rating/. This rating is computed from github.com/api-evangelist/immunebridge: open an issue to ask a question, or submit a pull request to add artifacts. Want it done for you? Prioritized profiling — $2,500 →

Security Posture 1

Authentication, domain security, vulnerability disclosure, and trust-center signals.

Immunebridge Domain Security

TLSv1.3 · HSTS · DMARC

SECURITY

Resources

Access & Security 1

Authentication, authorization, and security posture

DomainSecurity
DomainSecurity

Commercial 1

Pricing, plans, and the legal terms of use

PrivacyPolicy
PrivacyPolicy

Company 2

The organization behind the API

Website
Website
 Blog
Blog

Source (apis.yml)

apis.yml Raw ↑ 
aid: immunebridge
name: ImmuneBridge
description: ImmuneBridge is a San Francisco biotech company building a first-in-class integrated screening and manufacturing
  platform for allogeneic cell therapies. The company screens and expands stem cells from multiple sources (umbilical cord
  blood, mobilized blood, bone marrow), uses high-throughput automated assays with machine-learning models to predict donor
  and process performance early, and scales production with IBR403, a small molecule enabling up to 100,000-fold expansion
  of hematopoietic stem cells. The stated goal is to manufacture tens of thousands of affordable, high-quality immune cell
  doses (HSCs, NK cells, T cells, and more) from a single cord blood unit. ImmuneBridge is backed by Insight Partners, NFX
  Bio, M Ventures, and other institutional investors. This profile was enriched by the API Evangelist pipeline; the company
  publishes no public API or developer surface.
url: https://raw.githubusercontent.com/api-evangelist/immunebridge/refs/heads/main/apis.yml
accessModel:
  pricing: unknown
  onboarding: unknown
  trial: false
  try_now: false
  public: false
  label: Unknown
  confidence: low
  source: []
  generated: '2026-07-22'
  method: derived
image: https://cdn.prod.website-files.com/68d83bf74448ab977940e693/68db372f2c222ae10049d240_IB%2BHorizontal%2BLogo%2BBlack.webp
x-type: company
x-source: vc-portfolio
x-backed-by:
- insight-partners
x-tier: stub
x-tier-reason: portfolio-lead
specificationVersion: '0.20'
created: '2026-07-17'
modified: '2026-07-19'
tags:
- Company
- Biotech
- Cell Therapy
- Therapeutics
- Immunology
- Bioprocessing
- Life Sciences
apis: []
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
common:
- type: DomainSecurity
  url: security/immunebridge-domain-security.yml
- type: Website
  url: https://www.immunebridge.com/
- type: Blog
  url: https://www.immunebridge.com/blog
- type: PrivacyPolicy
  url: https://www.immunebridge.com/privacy-policy
x-enrichment:
  date: '2026-07-19'
  status: backfilled
  pass: local-v1
  note: backfilled from .gitignore signal + verified work evidence